These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 28890363)

  • 1. Relationship between the color stability and impurity profile of cefotaxime sodium.
    Sun H; Cui X; Liu B; Zhang J
    J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Sep; 1063():235-244. PubMed ID: 28890363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute and genotoxic profile of a dimeric impurity of cefotaxime.
    Agarwal SK; Bhatnagar U; Rajesh N
    Int J Toxicol; 2004; 23(1):41-5. PubMed ID: 15162846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stability of cefotaxime sodium in solid state.
    Zajac M; Musiał W; Pawłowski L
    Pharmazie; 2000 Dec; 55(12):917-8. PubMed ID: 11189867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stability of doripenem in vitro in representative infusion solutions and infusion bags.
    Psathas PA; Kuzmission A; Ikeda K; Yasuo S
    Clin Ther; 2008 Nov; 30(11):2075-87. PubMed ID: 19108795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study of the polymerized impurities in cefotaxime sodium and cefepime by applying various chromatographic modes coupled with ion trap/time-of-flight mass spectrometry.
    Ren X; Zhu B; Gao J; Tang K; Zhou P; Wang J
    Talanta; 2022 Feb; 238(Pt 2):123079. PubMed ID: 34808572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isolation and characterization of degradation products of moxidectin using LC, LTQ FT-MS, H/D exchange and NMR.
    Awasthi A; Razzak M; Al-Kassas R; Greenwood DR; Harvey J; Garg S
    Anal Bioanal Chem; 2012 Nov; 404(8):2203-22. PubMed ID: 22986987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Individual degradation rate constants for cefotaxime, deacetylation profile.
    Fabre H; Blanchin MD; Mandrou B; Bergé G
    Farmaco; 1989; 44(7-8):695-702. PubMed ID: 2590367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The stability of biapenem and structural identification of impurities in aqueous solution.
    Xia M; Hang TJ; Zhang F; Li XM; Xu XY
    J Pharm Biomed Anal; 2009 May; 49(4):937-44. PubMed ID: 19278804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Forced degradation and impurity profiling: recent trends in analytical perspectives.
    Jain D; Basniwal PK
    J Pharm Biomed Anal; 2013 Dec; 86():11-35. PubMed ID: 23969330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and isolation of chlorhexidine digluconate impurities.
    Revelle LK; Doub WH; Wilson RT; Harris MH; Rutter AM
    Pharm Res; 1993 Dec; 10(12):1777-84. PubMed ID: 8302766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality of cefotaxime sodium preparations.
    Wetterich U; Mutschler E
    Arzneimittelforschung; 1995 Jan; 45(1):74-80. PubMed ID: 7893275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study of forced degradation behavior of enalapril maleate by LC and LC-MS and development of a validated stability-indicating assay method.
    Bhardwaj SP; Singh S
    J Pharm Biomed Anal; 2008 Jan; 46(1):113-20. PubMed ID: 17964751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study on the compatibility of cefotaxime with tinidazole in glucose injection.
    Guo P; Li X; Wang J; You A
    J Pharm Biomed Anal; 2007 Apr; 43(5):1849-53. PubMed ID: 17336022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Compatibility of clindamycin phosphate with cefotaxime sodium or netilmicin sulfate in small-volume admixtures.
    Foley PT; Bosso JA; Bair JN; Townsend RJ
    Am J Hosp Pharm; 1985 Apr; 42(4):839-43. PubMed ID: 4014236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A validated stability-indicating LC method for acetazolamide in the presence of degradation products and its process-related impurities.
    Srinivasu P; Subbarao DV; Vegesna RV; Sudhakar Babu K
    J Pharm Biomed Anal; 2010 May; 52(1):142-8. PubMed ID: 20053517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetics and mechanism of degradation of cefotaxime sodium in aqueous solution.
    Berge SM; Henderson NL; Frank MJ
    J Pharm Sci; 1983 Jan; 72(1):59-63. PubMed ID: 6298400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stability of cefotaxime sodium as determined by high-performance liquid chromatography.
    Das Gupta V
    J Pharm Sci; 1984 Apr; 73(4):565-7. PubMed ID: 6327966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Photodegradation paths of cefotaxime.
    Lerner DA; Bonnefond G; Fabre H; Mandrou B; Simeon de Buochberg M
    J Pharm Sci; 1988 Aug; 77(8):699-703. PubMed ID: 3062165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isolation and characterization of process related impurities and degradation products of bicalutamide and development of RP-HPLC method for impurity profile study.
    Nageswara Rao R; Narasa Raju A; Narsimha R
    J Pharm Biomed Anal; 2008 Feb; 46(3):505-19. PubMed ID: 18162355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A validated stability-indicating RP-HPLC method for levofloxacin in the presence of degradation products, its process related impurities and identification of oxidative degradant.
    Lalitha Devi M; Chandrasekhar KB
    J Pharm Biomed Anal; 2009 Dec; 50(5):710-7. PubMed ID: 19632800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.